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1. Introduction 
The macula or macula lutea (originally from Latin macula, “spot” and lutea, “yellow”) is an 
oval-shaped spot, five mm in diameter, located temporal to the optical nerve and near the 
centre of the human retina. Although it comprises only a small part of the retina, it is 
responsible for the sharp central vision and colour vision. Age-related macular degeneration 
(AMD) is a disease in which the neuroretina and retinal pigment epithelia (RPE) of the 
macula degenerate with age resulting in profound loss of visual function. At the early 
stages, so called age-related maculopathy, patients present with “drusen”, the “biological 
waste materials” deposition, between RPE cells and the choroid especially in the macular 
region (Coleman et al. 2008, Jager et al. 2008). Visual acuity is normally not affected at this 
stage. As disease progresses to the advanced stages, patients may lose their central vision. 
There are two forms of advanced AMD: dry and wet. Dry-AMD also called central 
geographic atrophy. Apoptosis of RPE cells and subsequent death of photoreceptors in the 
macula underlie the pathology of dry-AMD (Coleman et al. 2008).  “Wet” AMD refers to the 
neovascular or exudative form of the disease and is associated with rapid vision loss caused 
by the infiltration of abnormal blood vessels from the choroid into the subretinal space 
leading to haemorrhage, leakage of fluid and eventual scar tissue formation (Chopdar et al. 
2003, Coleman et al. 2008). Dry-AMD is more common than wet-AMD accounting for nearly 
85~90% of AMD cases; however, wet-AMD contributes to 90% of severe vision loss resulting 
from AMD (Chopdar et al. 2003). In addition, AMD is generally thought to progress along a 
continuum from atrophic or dry-AMD to neovascular (wet) AMD with approximately 10-
15% of all AMD patients eventually developing the wet form (Sunness et al. 1999). 
Occasionally, patients can also present with exudative (wet) AMD as the first manifestation 
of the condition without prior signs of dry-AMD. 
1.1 The social and economic burden of age-related macular degeneration 
AMD is not painful. However, it affects the central vision and patients with AMD may 
have a distorted, or blurred vision (early AMD), or even a total loss of central vision 
(advanced AMD), and they cannot see things in details. It is therefore, very difficult for 
them to cope with daily life on their own. AMD is the largest cause of blindness in most 
developed countries. More than half a million people in the UK suffer from AMD with 
over half of all registrations of severe visual impairment attributed to the disease (Bunce 
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and Wormald. 2006). The incidence of AMD is predicated to increase as the proportion of 
the elderly increases and this will have a major impact on morbidity with implications for 
economic and social cost. For example, a recent analysis of AMD in Australia shows that 
current treatment in AMD costs society $2.6 billion per year; this figure is predicted to rise 
to $6.5 billion by 2025 and a total of $59 billion over the next 20 years will be needed for 
AMD management. (Taylor H, Guymer R, Keeffe J. 2006). In the UK, the anti-vascular 
endothelial growth factor A (VEGF-A) antibody, Ranibizumab (Lucentis) is approved by 
the National Health Service (NHS) for neovascular AMD therapy. Based on the  
information  published in 2008, there are about 26,000 new cases of neovascular AMD 
each year in England (http://www.nice.org.uk/nicemedia/pdf /TA155guidance.pdf). 
The estimated cost to NHS for Lucentis alone is about £1.3 billion/year in England. The 
social and economic cost for caring and treating AMD is huge. A search for effective ways 
to prevent or treat AMD is urgent.  
2. Inflammation in age-related macular degeneration 
2.1 Para-inflammation and retinal aging 
To develop an effective and safe therapy for AMD, it is important that we understand the 
cause and the pathogenesis of the disease. Although a lot of risk factors of AMD have been 
identified, the precise mechanism on how these risk factors lead to macular damage remains 
ill-defined. Inflammation is believed to play an important role in AMD. How is 
inflammation initiated in the aging retina? According to Harman’s “free radical theory of 
aging” (Harman. 1956), aging is the accumulation of free-radical induced damage in cells 
and tissues. We have shown previously that a number of oxidized materials, including 
nitrotyrosine, oxidized low-density lipoprotein (LDL), and oxidized protein (identified by 
dinitrophenyl (DNP) staining) accumulate in the aging retina (Xu et al. 2009) (Figures 1A-
1E). These oxidized (or damaged) molecules represent an endogenous threat to normal 
tissue physiology. However, under normal aging conditions, overt pathology does not occur 
in the retina. We now understand that the immune system has evolved to clear senescent, 
damaged cells and maintain normal tissue functions. Cells of the innate immune system, 
such as tissue resident macrophages sense signals from damaged cells/molecules and 
mount a para-inflammatory response, a concept proposed by Medzhitov (Medzhitov. 2008) 
as a “physiological” inflammatory response. Para-inflammation describes a “physiological” 
inflammatory process that lies between the overt destructive inflammation and normal 
quiescent state, and is required for tissue homeostatic processes in clearing damaged cells 
and molecules (Medzhitov. 2008). In the retina, RPE and photoreceptors encounter age-
related increases in oxidative or metabolic stress. We have shown previously that age-
related retinal “para-inflammation” comprises (1) microglial activation and subretinal 
migration (Figure 1F); and (2) complement activation (Figures 1G, 1H) (Chen et al. 2010, Xu 
et al. 2009). This para-inflammatory response may protect the retina from age-related free 
radical mediated damage as overt retinal pathology does not occur under physiological 
aging conditions (Chen et al. 2010, Xu et al. 2009). The protective effect of the para-
inflammatory response is, however, limited. During aging, the noxious stimuli persist for 
many decades, which will inevitably result in loss of functional cells and molecules; the host 
has evolved to adjust the thresholds to maintain tissue function as well as to avoid an overt 
inflammation (Medzhitov. 2008). 
www.intechopen.com
 Inflammation in Age-Related Macular Degeneration – Implications for Therapy 
 
131 
 
Fig. 1. Oxidative stress and para-inflammation in the aging retina (Xu et al. 2009). (A-E), 
Cryosections of mouse eyes were stained for dinitrophenyl (DNP, red) and DAPI (blue). A 
weak positivity of DNP was observed in the retina (A) and RPE/choroid (C) of 3-month old 
mice. DNP was strongly positive in the retina (B) and RPE/choroid (D) of 24 month old 
mice. (E), Isotype control staining did not reveal any positivity. (F), Subretinal macrophages 
in a 20 months old mouse.  RPE/choroidal flatmounts were stained for F4/80 (red) and Iba-
1 (green) and observed by confocal microscopy. The majority of subretinal macrophages are 
F4/80+Iba-1+. A small number of cells were F4/80+Iba-1-. (G, H), Complement C3d 
deposition in mouse retina. Cryosections of mouse eye were stained for C3d (green) and 
propidium iodide (PI, red) and observed by confocal microscopy. C3d was not detected in 
the retina of a 3-month old mouse (G), but detected at the retina/choroidal interface in a 24-
month old mouse (H).  Ch, choroid; INL, inner nuclear layer; ONL, outer nuclear layer; RPE, 
retinal pigment epithelium.  
2.2 Evidence of the role of inflammation in AMD 
Evidence supporting the association between chronic inflammation and AMD emerged over 
25 years ago. In donated human AMD eyes, Penfold et al detected inflammatory cells 
(macrophages, lymphocytes and mast cells) in the choroid (Penfold et al. 1985, Penfold et al. 
1997). Drusen, the hallmark of early AMD, also contains a variety of inflammatory 
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molecules including vitronectin, amyloid A/P, Factor X, prothrombin, and in some 
instances, immunoglobulin, HLA-DR, complement C3, C5, C5b-9, CFH, and CRP (Anderson 
et al. 2002). These results suggest that a local chronic inflammatory response is associated 
with AMD pathology.  
Data from population-based epidemiological studies suggest that chronic systemic 
inflammation may also play a role in AMD. The acute-phase serum protein, C-reactive 
protein (CRP) is a “golden” marker of systemic inflammation. Increased serum CRP level 
has been shown to be associated with AMD in a number of studies (McGwin et al. 2005, 
Schaumberg et al. 2007, Seddon et al. 2004, Seddon et al. 2005). In addition, elevated 
circulating levels of inflammatory cytokines, including IL-6 (Seddon et al. 2005), and TNF- 
(Cousins et al. 2004), and soluble intercellular adhesion molecule 1 (sICAM-1) (Klein et al. 
2005) have been reported to be related to AMD. A few studies also detected retinal 
autoantibodies in AMD patients (Cherepanoff et al. 2006, Gu et al. 2003, Penfold et al. 1990). 
More recently, clinical studies have shown that AMD patients appear to have a higher 
complement activity in the serum as compared age-matched non-AMD controls (Reynolds 
et al. 2009, Scholl et al. 2008). These data suggest that AMD is related to a chronic systemic 
inflammation. 
Whilst clinical studies support the link between AMD and inflammation, data from 
experimental animal studies further suggest a causal role of inflammation in AMD. In the 
laser-induced choroidal neovascularisation (CNV, an animal model for wet AMD), 
complement activation has been detected at the lesion site (Bora et al. 2005) and blocking the 
complement activation by CFB siRNA attenuated CNV (Bora et al. 2006). Mice deficient in 
the complement regulatory protein CD59 developed early and severe CNV, whereas 
administration of a recombinant soluble form of mouse CD59a-Fc (Bora et al. 2007) or 
membrane-targeted form of CD59 inhibited the growth of CNV (Bora et al. 2010). Infiltrating 
bone marrow-derived macrophages are also crucial for the development of CNV (Galimi et 
al. 2005), and depletion of macrophages reduced the size, cullularity and vascularity of CNV 
(Espinosa-Heidmann et al. 2003, Sakurai et al. 2003). Animals with certain macrophage 
deficiencies (e.g. Ccl2, Ccr2, Cx3cr1 or ccl2/cx3cr1) (Ambati et al. 2003, Combadiere et al. 
2007, Tuo et al. 2007) develop retinal lesions akin to human AMD, although the precise 
mechanism remains poorly defined.  
2.3 Immune pathways 
There are two arms of the immune system: the innate immune system and adaptive immune 
system. The innate immune system provides a rapid but non-specific response to pathogens 
(e.g. foreign organisms and altered self antigens); whereas the adaptive immune system 
offers an antigen-specific response. Although there is evidence that chronic C. Pneumoniae 
infection might be related to AMD (Baird et al. 2008, Ishida et al. 2003, Kalayoglu et al. 2003), 
accumulation of free radical-mediated damage on tissue cells and extracellular molecules at 
the macular area is the main detrimental factor. The innate immune system, particularly the 
phagocytes and the complement system, plays an important role in the clearance of 
apoptotic cells and damaged/altered extracellular matrix components. The innate immune 
system may be the main contributor of the chronic inflammation related to AMD, and this 
view is supported by various genetic and experimental animal model studies (see below). 
The adaptive immune system may also contribute to AMD-related chronic inflammation 
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albeit to a less extent. Retinal autoantibodies have been detected in AMD patients 
(Cherepanoff et al. 2006, Gu et al. 2003, Penfold et al. 1990), and AMD-like lesions can be 
modelled in animals with DHL-immunization (Hollyfield et al. 2008).  
2.3.1 Complement pathway 
The complement system is an important part of the innate immunity. It complements the 
antibodies and phagocytes to clear pathogens from the host. The complement system 
consists of over 20 small proteins found in the blood; and the system can be activated by at 
least three pathways: the classic pathway (CP), mannose-binding lectin (MBL) pathway, and 
the alternative pathway (AP) (Figure 2). There are two critical steps for the full activation of 
the complement pathways: C3 cleavage and C5 cleavage respectively. A fully activated 
complement system results in the formation of the cell-killing membrane attack complex 
(MAC, or C5b-C9) (Figure 2). The key difference between different pathways rests on how 
the enzymes, i.e. C3 convertase and C5 convertase, are formed. The convertases of C3 and 
C5 of the CP and lectin pathway comprise the complement components C4bC2b and 
C4bC2bC3b respectively, while in the AP they are composed of C3bBb (C3 convertase) and 
C3bBbC3b (C5 convertase) (Figure 2) (Zipfel and Skerka. 2009). In addition, complement can 
also be activated by a pathway that acts independently of C3 to bypass the C3 convertase 
and is mediated by direct thrombin action on the C5 convertase (Huber-Lang et al. 2006). 
During the complement activation cascades a number of complement fragments are 
generated including C4a, C3a, C5a, and C3b. These complement fragments are 
inflammatory mediators and are involved in a variety of immune functions (Figure 2). C3b 
can opsonise antigens and apoptotic cells promoting the clearance of these antigens or cells 
by macrophages that express complement receptors (CR). Whereas C4a, C3a, and C5a are 
anaphylatoxins and can increase the permeability of blood vessels resulting in increased 
accumulation of plasma protein and leukocyte infiltration at the site of complement 
activation. They also have chemotactic roles, which induce neutrophil and lymphocyte 
migration (Figure 2). Therefore, a fully activated complement pathway can modulate the 
immune response at multiple levels. 
Compelling evidence suggests that complement activation is involved in AMD. Many 
complement components have been detected in drusen and AMD lesions (Anderson et al. 
2002, Anderson et al. 2010). Polymorphisms in a number of complement genes (CFH, CFB, 
C2, and C3) increase the risk of AMD (Edwards. 2008, Katta et al. 2009). However, there are 
many important questions remain to be answered. For example, is complement system 
simply over activated or is it dys-regulated in AMD? If it is over activated, a proper control 
of complement activation would be an option for therapy, but then we need to know which 
pathway is over activated in AMD. Evidence from genetic studies points to the direction of 
the alternative pathway since complement factor H, which has the biggest influence on 
AMD risk, is exclusively involved in this pathway. If the disease is caused by the dys-
regulation of the complement pathways, we must find out at which points the pathways are 
dys-regulated and how. An activated complement system may affect the immune response 
at multiple levels. A dys-regulation of the activation pathway at any step may result in a 
fatal consequence to the macula. Reduced opsonisation by C3b on apoptotic RPE cells or 
other noxious particles may lead to a delay in the clearance of these toxic materials; 
increased C4a, C3a or C5a fragments may cause unwanted inflammation at the site of 
complement activation. The detailed role of complement activation in AMD lesion 
formation warrant further investigation.  
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Fig. 2. Complement activation and immune regulation. Complement system can be 
activated by three pathways: the classical pathway (CP), mannose-binding lectin (MBL) 
pathway and the alternative pathway (AP); all lead to the cleavage of C3 and C5 and the 
formation of C5b-C9. Activation of the complement system generates C4a, C3a, C3b and C5a 
fragments that are actively involved in immune responses. C3b opsonises foreign antigens 
and apoptotic cells promoting phagocytosis. C4a, C3a and C5a are anaphylatoxins, which 
may cause increased vascular permeability enhancing inflammation. They are also potent 
leukocytes chemoattractants and can induce the migration of neutrophils and lymphocytes 
to the sites of complement activation. C5b-C9 may directly kill antibody coated particles.  
2.3.2 Monocytes and macrophages  
Monocytes are a subset of circulating white blood cells that are originated from bone 
marrow haematopoietic stem cells. Monocytes migrate from the bloodstream to peripheral 
tissues and then differentiate into tissue resident macrophages or dendritic cells. In the 
central nervous system, they differentiate into brain (or retinal) resident macrophages, and 
these cells are traditionally called microglial cells. Monocytes and macrophages, dendritic 
cells are important components of the innate immune system and play a crucial role in 
detecting antigens (including non-self foreign antigens and altered self antigens) and the 
removal of the antigens as well as apoptotic cells in pathophysiological conditions.  
Pathologies in AMD are restricted to the retina-choroid interface. Choroidal macrophages 
and retinal microglial cells are major immune cells involved in the pathological process. 
Under normal physiological conditions, subretinal space (the interface between the retina 
and RPE/choroid) is devoid of any immune cells. However, in the aging eye, microglia and 
macrophages accumulate not only in the subretinal space, but also in the choroid (Xu et al. 
2009). Presumably, this form of para-inflammation is a protective response to RPE or 
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photoreceptor damage in the aging eye. Subretinal microglial cells may remove apoptotic 
RPE cells or damaged photoreceptors, whereas choroidal macrophages scavenge waste 
materials produced by RPE cells preventing drusen formation. These cells are, therefore, 
crucial for retinal homeostasis, and dys-function or mal-function of these cells may result in 
macular pathology at the retina-choroid interface (AMD lesions).  
Compelling evidence suggests that macrophages may play a detrimental role in AMD. 
Polymorphisms in chemokine receptor cx3cr1 gene, a gene that is widely expressed by 
myeloid-derived cells, increase the risk of AMD (Tuo et al. 2004, Yang et al. 2010). Animals 
with monocyte dysfunction due to lack of certain chemokine (e.g. CCL2) (Ambati et al. 2003) 
or chemokine receptors (CCR2, or CX3CR1) (Ambati et al. 2003, Combadiere et al. 2007, Tuo 
et al. 2007) develop AMD-like lesions. Furthermore, in the laser-induced wet AMD animal 
model, retinal lesion can be attenuated by macrophage depletion (Espinosa-Heidmann et al. 
2003, Sakurai et al. 2003). The precise mechanism underlying the detrimental effect of 
macrophages to AMD remains to be elucidated.  
2.4 Age-related macular degeneration - an imbalance between macular damage and 
para-inflammation? 
Under normal physiological aging conditions, the para-inflammatory response, which is 
characterized by complement activation and microglia/macrophage activation and 
subretinal migration (Figure 1) (Xu et al. 2009), protects the macula against the age-related 
free radical-mediated damage. This suggests that microglia and complement activation are 
beneficial to retinal aging. However, under pathological conditions, these two arms of 
innate immune pathways are harmful and their activation leads to macular damage, such as 
in AMD. How is the outcome of their activation determined? In other worlds, activation of 
microglia and the complement system at the macular site occurs in all aged people, why 
some people develop AMD, some others do not?     
In order to maintain a healthy functional macula, the level of age-related free radical-
mediated tissue/cell damage and the capacity of the immune system to cope with 
accelerating damage (via para-inflammatory response) needs to be balanced (Figure 3). In 
persons who have a relatively healthy lifestyle (hence the age-related oxidative damage 
accumulates at the average level during the process of aging), and have no genetic 
predispositions to AMD (hence be able to maintain a good defence system), their immune 
system can maintain macular homeostasis throughout their life and AMD will not occur 
(Figure 3A). In persons who do not have a healthy lifestyle (e.g. heavy smokers, high-fat 
diet, and extensive light exposure throughout their life), even if they do not have any 
genetic predispositions to AMD, the age-related free radical-mediated macular damage may 
exceed the repair capacity of the para-inflammatory response, macular function may decline 
and overt pathology (AMD) may ensure (Figure 3B). On the other hand, if the person has a 
healthy lifestyle and the age-related free radical-mediated damage accumulates at a normal 
level in the macula, but he/she has genetic predispositions to AMD, and the immune 
system is unable to initiate a functional para-inflammatory response, macular pathology 
(AMD) may also occur (Figure 3C). Needless to say, if a person has an unhealthy lifestyle, 
and he/she is unfortunate enough to have genetic risk factors, his/her risk to develop AMD 
is significantly higher than others.  
In terms of the immune response, during the disease initiation stage, the para-inflammatory 
responses are protective (although they may not be able to fully protect the macula). The 
inducer of para-inflammation is a low-grade chronic macular damage, and pathways involved 
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are monocytes, macrophages and the complement system (Xu et al. 2009). Once the disease 
begins, an overt inflammation, instead of para-inflammation, may occur. At this stage, the 
inducers are toxic molecules released by dead cells and altered extracellular molecules. In 
addition to monocytes, macrophages (Penfold et al. 1985, Penfold et al. 1997) and the 
complement system, other immune components such as T and B lymphocytes, and 
autoantibodies (Penfold et al. 1985, Penfold et al. 1990) may also be involved in inflammation 
at this stage. The physiological purpose of the inflammation is to remove dead cells, tissue 
debris and other toxic molecules and to promote tissue repair and remodelling. However, like 
in many other disease conditions, inflammation is a double-edged sword. Activated immune 
cells may release inflammatory cytokines and chemokines such as TNF-and IL-1, and 
further tissue damage (so called collateral damage) (Nathan. 2002) is unavoidable.  
The concept that AMD is related to an imbalance between the level of age-related macular 
damage and the protective capacity of the immune system is supported by evidence from 
numerous epidemiological and genetic studies. Over the last decades epidemiological 
studies have identified a number of environmental factors that may increase the risk of 
AMD, including smoking (Baird et al. 2008, Chakravarthy et al. 2007, Cong et al. 2008, 
DeBlack. 2003, Hughes et al. 2007, Khan et al. 2006, Thornton et al. 2005), high-fat diet 
(Evans. 2001), sunlight exposure (Hirakawa et al. 2008, Plestina-Borjan and Klinger-Lasic. 
2007) and alcohol consumption (Chong et al. 2008). Cigarette smoking is the single most 
important environmental risk factor for AMD. Current smokers have 45% greater 
probability of developing AMD and exhibit enhanced disease progression when compared 
to non-smokers (Klein et al. 2008). Although the mechanism underlying the environmental 
factors mediated increased risk of AMD is not known, it is believed that they may increase 
macular damage and/or alter the immune function. Taken cigarette smoking as an example, 
the blood borne products of tobacco combustion damage RPE cells, alter Bruch’s membrane 
and exacerbate sub-PRE deposition (Bertram et al. 2009, Espinosa-Heidmann et al. 2006, Jia 
et al. 2007, Wang et al. 2009). Such lesions can be experimentally induced in vivo and in 
vitro after exposure to cigarette smoke (Espinosa-Heidmann et al. 2006, Wang et al. 2009), or 
defined extracts such as hydroquinone (HQ) (Espinosa-Heidmann et al. 2006, Wang et al. 
2009), polycyclic aromatic hydrocarbons (PHA) (Espinosa-Heidmann et al. 2006, Wang et al. 
2009) and acrolein (Jia et al. 2007). Cigarette smoking also affects the immune system 
(Arnson et al. 2010, Klareskog et al. 2007), including the ocular immune responses. Cigarette 
smoking increases the incidence of uveitis (Lin et al. 2010, Lois et al. 2008, Thorne et al. 
2008)and scleritis (Boonman et al. 2005), and enhances the risk of developing cystoid 
macular oedema in uveitis patients (Lin et al. 2010, Thorne et al. 2008). It appears, therefore, 
that cigarette smoking can cause macular damage, and alter the immune system resulting in 
a declined para-inflammatory response.  
In addition to environmental factors, clinical studies have found that the risk of AMD is also 
affected by genetic factors. Genes that are involved in AMD susceptibility fall into three 
categories: immune-related genes (CFH, CFB, C2, C3, C5, Cx3cr1, TLRs, IL-8, HLAs), 
mitochondrial and oxidative stress-related genes (ARMS2 and HTRA1) and extracellular 
matrix related genes (PRELP, LAMC1, LAMC2, LAMB3, FIBULIN2, and ITGB4) (Katta et al. 
2009). Importantly, the majority of the immune-related genes are related to the innate 
immunity, including the complement system (CFH, CFB, C2, C3 and C5) (Lotery and Trump. 
2007, Montezuma et al. 2007), and monocyte/macrophage functions (Cx3cr1 (Chan et al. 2005, 
Combadiere et al. 2007, Tuo et al. 2004, Yang et al. 2010) and TLRs (Kaarniranta and Salminen. 
2009)). These data suggest that genetic factors may predispose individuals to the risk of AMD 
by (1) decreasing the anti-oxidative ability, and/or (2) altering the immune function.  
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Fig. 3. The balance between oxidative damage and para-inflammation in retinal aging.  
(A) Under normal physiological conditions, oxidative damage accumulates at the macula 
with age. A healthy immune system can mount a para-inflammatory response to remove 
damaged molecules/cells and maintain macular function. The level of damage is within the 
capacity of the immune system and pathology (AMD) will not occur. 
(B) When the level of stress-mediated macular damage exceeds the capacity of the immune 
system (as a result of unhealthy life style, anti-stress related gene mutations, etc), the 
damaged molecules and cells may not be cleared away through the para-inflammatory 
response. The damaged cells and oxidised molecules are toxic and may cause further 
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damage to surrounding healthy cells causing AMD. They may also initiate an overt 
inflammation, which can further damage the macula resulting in AMD.  In this case macular 
damage may be caused predominately by oxidative insults, although inflammation 
(secondary to tissue damage) may also play a role. 
(C) When the immune system is dys-regulated (as a result of immune-related gene 
mutation), instead of a protective para-inflammatory response, an overt inflammation may 
occur in response to oxidative stress-mediated, age-related macular damage. This may 
include uncontrolled complement activation and excessive macrophage infiltration at the 
macula. Macular damage is predominately mediated by inflammation.  
Studies from AMD animal models further support this concept. There are a few AMD 
animal models reported over the past ten years; and the animals that develop AMD-like 
changes can be classified into two categories: animals with monocyte or complement gene 
deficiency and animals are defect in anti-oxidative stress. Mice in the first category include 
the CCL2-/-, CCR2-/-(Ambati et al. 2003), CX3CR1-/- (Combadiere et al. 2007), 
CCL2/CX3CR1 double knockout (DKO) mice (Tuo et al. 2007), and the CFH-402 transgenic 
mice (Ufret-Vincenty et al. 2010). CCR2 and CX3CR1 are important chemokine receptors 
expressed by different subsets of blood monocytes (Boring et al. 1997, Boring et al. 1997, 
Geissmann et al. 2003, Imai et al. 1997, Lu et al. 1998, Wong and Fish. 2003). CCR2 has 
multiple ligands (CCL2, CCL8, and CCL12), whereas CX3CR1 only binds fractalkine (Imai et 
al. 1997). Ligation of CCR2 or CX3CR1 results in monocyte migration and activation, and 
they are important to maintain a normal monocyte function. Although the precise 
mechanism underlying retinal damage in these mice is poorly defined, the models suggest 
that a disruption in the innate immune system, particularly the monocytes and complement 
pathways may dysfunction the para-inflammatory response resulting in age-related retinal 
damages. Models in the second category include the SOD-1 deficient mice (Hashizume et al. 
2008), the apoE4 mice (Malek et al. 2005), and the apoB100 transgenic mice (Fujihara et al. 
2009). These mice develop AMD-like lesions due to either decreased anti-oxidant function or 
increased accumulation of noxious materials in the retina.  
3. Implications for AMD therapy 
3.1 Current treatments 
At the early stages of AMD (age-related maculopathy), patients have a normal vision and 
clinical intervention is not required. Although we know that the disease may progress to 
advanced stages, there are no preventive therapies for early AMD. For advanced AMD, due 
to lack of knowledge on the pathogenesis of dry-AMD, currently there is no effect therapy 
for this type of disease. Choroidal neovascular membrane (CNV) underlies the pathology of 
wet-AMD. The abnormal blood vessels cause haemorrhage and leak fluid into the macula. 
There are a few therapies all aimed to remove CNVs, including the thermal laser 
photocoagulation therapy introduced in 1980’s, photodynamic therapy in 1990’s, and more 
recently the biologic therapies that target the vascular endothelial growth factor (VEGF). 
Photocoagulation therapy produces multiple burns at the CNV lesion site using a thermal 
laser (Argon laser) to destroy CNV. The therapy was able to reduce vision loss in some 
patients, but the benefits were inconsistent, the risks were substantial, and recurrences were 
frequent (Virgili and Bini. 2007). The therapy was unable to improve vision. Further, since 
the laser also destroys the choriocapillaris, RPE cells and photoreceptors resulting in a blind 
spot, this therapy is only suitable for people with lesions that are outside the centre of the 
macula (fovea).  
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Photodynamic therapy (PDT) was introduced in 2000. PDT involves an intravenous 
injection of a photosensitizing drug called Verteporfin. The drug is carried out by blood 
lipoproteins and reaches to the site of CNV in the macula. A non-thermal laser (blue laser at 
689 nm) is then used to sensitize the drug, and this photochemical reaction produces 
cytotoxic free radicals resulting in direct cellular injury to vascular endothelial cells and 
subsequent regression of CNV. Clinical studies have shown that PDT is much less 
destructive and achieves better results for vision than photocoagulation (Spaide et al. 2003). 
Blood vessels that have been eradicated in this way do now grow back, however other 
vessels may still be formed if angiogenic stimuli persist. Clinical studies have shown that 
PDT is safe and effective for treating  a range of lesions, including predominant classic 
lesions, CNV secondary to pathological myopia and occult with no classic subfoveal lesion, 
but it has no effect on minimally classic lesions (Spaide et al. 2003). It should be noted that 
PDT does not improve vision (Bressler et al. 2009).  
The most recent treatment to be developed is called Anti Vascular Endothelial Growth 
Factor (Anti –VEGF) drug therapy (Campa and Harding. 2011). Anti-VEGF therapy involves 
blocking the VEGF-A, an important and essential growth factor that is involved in the 
breakdown of blood-retinal barrier (BRB) (thus the leakage of blood components and 
macular oedema) and the growth of new blood vessels (CNV) (Bressler. 2009). Therefore, 
this therapy will make its effect by stabilising tight-junctions of the BRB and inducing 
regression of the neovascularisation once formed. There are three main drugs used in this 
category of treatment: Macugen, Lucentis and Avastin. The drugs are administered 
intravitreally, and the therapy needs to be repeated a number of times.  
Macugen was the first drug that was approved by the US Food & Drug Administration 
(FDA) in 2004 and by the European Medicines Evaluation Agency (EMEA) in 2006. Clinical 
studies have shown that Macugen is more effective than PDT at slowing vision loss, but it 
does not improve visual acuity (Edwards et al. 2008, Gragoudas et al. 2004, VEGF Inhibition 
Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group et al. 2006). The 
reason for this is probably because it only targets the VEGF-165 isoform.  Lucentis is another 
anti-VEGF antibody that targets all isoforms of VEGF, and it was released one year after 
Macugen. Clinical evidence suggests that Lucentis can substantially improve visual acuity in 
wet-AMD patients (Bressler et al. 2009, Brown et al. 2006, Rosenfeld et al. 2006). Avastin is 
another anti-VEGF drug and is approved for the treatment of advanced colorectal disease, 
and it has similar properties to Lucentis. However, it is a full-length antibody and is much 
less expensive than Lucentis. A recent study has shown that Avastin has the same effect as 
Lucentis in treating wet-AMD, although it may have a slightly higher cardiovascular side 
effect (Arevalo et al. 2010, Campa and Harding. 2011, Giansanti et al. 2007). Although the 
drugs that inhibit VEGF prevent vision loss, and even improve visual acuity in some cases 
of wet AMD, their effect on improving vision depends greatly on the time at which they are 
administered and there is a huge variability in functional outcomes. A recent study on 
Avastin treatment for wet AMD (Arevalo et al. 2010) reported functional outcomes and 
showed that after 2 years treatment, 43.5% of cases had improved vision, 43% remained 
stable and 13.5% had decreased vision (even with >10 injections within 24 months) (Arevalo 
et al. 2010). The anti-VEGF therapy, although is better than PDT and other treatments for 
wet AMD, has its limitations and side effects. More target-specific, safe and effective 
therapies are urgently needed for both dry and wet AMD.   
3.2 Immune therapy - a future for Age-related macular degeneration?  
The importance of inflammation in AMD pathology offers an opportunity for therapy. 
Based on the “oxidative stress/para-inflammation balance” theory of AMD, the disease can 
www.intechopen.com
 Inflammatory Diseases – Immunopathology, Clinical and Pharmacological Bases 
 
140 
be theoretically prevented or at least delayed if we know where the unbalance is. By living 
in a healthy lifestyle (avoid the environmental risk factors), we can minimise the age-related 
oxidative stress. In reality, however, we can chose healthy food, but we may have a very 
limited choice on the environment that we live. With advanced gene therapy technology, in 
the future, we might be able to reduce the genetic risk factors of AMD. Once the disease 
begins, we must treat the disease. We know that inflammation may have dual roles in 
disease progression stages. How can we modulate the immune system to treat AMD?  
3.2.1 Is non-specific anti-inflammatory therapy beneficial to AMD?  
Regardless the cause of AMD, once the disease begins inflammation inevitably contributes to 
macular damage (either as a passive or a collateral damage). We now know that inflammation 
is involved in both dry and wet AMD, although the detailed immune pathway involved is not 
fully defined.  There are many anti-inflammatory drugs that can suppress immune activation. 
Can AMD patients benefit from systemic non-specific immune suppressions? Early clinical 
studies have investigated the beneficial effect of systemic immune suppression in AMD, 
including certain steroids and non-steroid anti-inflammatory drugs (NSAIDs). The results, 
however, are inconsistent between different studies. For instance, a few studies have shown 
that intravitreal injection of triamcinolone, an anti-inflammatory steroid with angiostatic effect, 
improves visual acuity in exudative macular degeneration patients (Jonas et al. 2003, Jonas et 
al. 2004, Penfold et al. 1995). In addition, posterior juxtascleral injection of anecortave also 
improves the symptoms in wet AMD patients (Russell et al. 2007). Patients on long-term anti-
inflammatory treatment for other diseases appear to have significantly lower lifetime 
prevalence of AMD (McGeer and Sibley. 2005). A more recent randomized pilot study shows 
that systemic immunosuppression can reduce the number of intravitreal anti-VEGF injection 
in wet AMD (Nussenblatt et al. 2010). However, an earlier Blue Mountains Eye Study 
indicated that administration of NSAIDs or corticosteroids did not reduce the prevalence of 
either early or late AMD (Wang et al. 2003). Therefore, the non-specific immune suppression 
therapy has a limited beneficial effect in AMD.  
3.3 Is complement suppression a future therapy for AMD? 
Complement activation is believed to be involved in AMD pathology. Can AMD be treated 
by blocking complement activation? People from pharmaceutical companies seem to believe 
so, and in fact, a few complement inhibitors are already in phase 1/2 clinical trials for AMD 
(http://www.ophthotech.com/products/arc1905/; 
http://clinicaltrials.gov/ct2/show/NCT00473928). These complement inhibitors (C3 or C5 
inhibitors) non-specifically block all pathways of complement activation. Whilst we are 
waiting for the outcomes of these clinical trials, let’s examine the mechanism and the likely 
benefits/side effects of the therapy.  
To understand whether complement inhibition will benefit all AMD patients, one of the 
important questions that we should be asking is whether complement activation is harmful 
in all AMD patients. Genetic studies have shown that around 30-50% of AMD patients do 
not have any polymorphisms in complement related genes (Edwards. 2008, Katta et al. 
2009). Furthermore, although serum complement activity is generally higher in AMD 
patients as compared to non-AMD controls, a significant number of AMD patients have a 
normal serum complement activity (Reynolds et al. 2009, Scholl et al. 2008). The results 
suggest that not all AMD patients have uncontrolled complement activation, in other words, 
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AMD pathology may occur in the absence of abnormal uncontrolled complement activation. 
To further test this hypothesis, we have examined the complement activation in the CCL2 
KO and CCR2 KO mice, the mouse models of AMD (Ambati et al. 2003). We found that 40% 
of CCL2 KO mice and 28% of CCR2 KO mice (>18 months old) develop retinal atrophies 
(Figure 4A) (Chen et al. 2011). Further mechanic study shows that there is no significant 
increase in the serum complement activity (Figure 4C). The expression levels of complement 
genes in the liver (figure 4D), retinal and RPE/choroidal tissue (data not shown) in the KO 
do not significantly differ from those in age-matched control mice. Furthermore, the 
complement system is only partially activated resulting in complement C3b but not C5b-C9 
deposition at the lesion site (Figure 4E, 4F) (Chen et al. 2011). The results suggest that retinal 
lesion in these mice is not caused by dys-regulated complement activation. Since C3b/C3d 
plays an important role in opsonising apoptotic cells, we believe this partial complement 
activation is beneficial. Complement activation in these mice is a consequence of retinal 
damage and the physiological purpose may be to promote the removal of apoptotic cells 
from the lesion site.  
 
 
Fig. 4. Complement activation in aged CCL2 KO or CCR2 KO mice. A, a fundus image of a 
24-m old C57BL/6 mouse showing multiple small white dots (correlated to subretinal 
microglia (Xu et al. 2008). B, a fundus image of a 24-m old CCL2 KO mouse showing patches 
of white lesions akin to human geographic atrophy (arrows). C, Serum complement activity 
determined by haemolytic assay. D, real-time RT-PCR analysis of complement gene 
expression in the liver tissue in different strains of mice. E & F, complement C3d (red) and 
C5b-9 (green) expression in retinal lesion in a 24-m old CCL2 KO mouse (E) and an 
experimental autoimmune uveoretinitis mouse (F, as a positive control). C5b-9 (green) was 
detected in uveoretinitis lesion but not in CCL2 KO mouse lesion (arrowheads). RPE, retinal 
pigment epithelium; Ch, choroid; ONL, outer nuclear layer (Chen et al. 2011). 
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So it appears that not all AMD has a complement component in its pathogenesis, and 
complement inhibition may not benefit every AMD patient. In patients whose macular 
pathology is not caused by uncontrolled complement activation, the therapy may even 
worsen the disease, as a partially activated complement system may help the clearance of 
dead cells and debris from the lesion site and promote tissue repair/remodelling. The 
efficacy and safety of complement inhibitors in AMD therapy warrant further investigation.  
3.4 Can we modify monocyte function to treat AMD? 
Genetic studies have shown that cx3cr1 gene polymorphism is a risk factor of AMD (Tuo et 
al. 2004, Yang et al. 2010), and this risk is independent of any complement gene 
polymorphisms (Yang et al. 2010). Our studies in the aged CCL2 KO and CCR2 KO mice 
show that AMD-like lesion can develop in the absence of any complement dys-regulation 
(Figure 4) (Chen, et al. 2011). The results suggest that under aging conditions, monocyte 
malfunction may result in macular damage in the absence of complement dys-regulation. 
Modulating the monocyte function may, therefore, offer an opportunity for therapy under 
this situation.  
 
 
Fig. 5. Bone marrow-derived macrophage (BMDM) function in CCR2- or CCL2-deficient 
mice. A, inflammatory cytokine gene expression in BMDMs. B, BMDM phagocytosis 
determined by the pHrodoTM E. coli Bioparticles Phagocytosis assay (Invitrogen). *, P<0.05; 
**, P<0.01; ***, P<0.001 compared to WT controls.  
To understand which functions of the monocyte are altered in CCL2 KO or CCR2 KO mice, 
we investigated the phenotype and function of bone marrow-derived macrophages 
(BMDMs) from WT and KO mice. Interestingly, there is no significant difference on BMDM 
phenotype between WT and KO mice. However, cells from the CCR2 KO or CCL2 KO mice 
expressed significantly more inflammatory genes iNOS and TNF- but less anti-
inflammatory gene IL-10 as compared to WT cells (Figure 5A). Furthermore, BMDMs from 
the KO mice also had significantly reduced phagocytic ability as compared to cells from WT 
mice (Figure 5B). It is possible, therefore, that in CCL2 KO and CCR2 KO mice, in response 
to age-related retinal damage, microglia and macrophages migrate to the subretinal space 
(Figure 1) (Xu et al. 2008). Their physiological role in the subretinal space is to remove 
damage cells and debris and promote tissue repair. However, they may be unable to do the 
job as they have a lower phagocytic ability. Instead, they may produce inflammatory 
molecules such as TNF- and nitric oxide, further damaging retinal tissue. Our results 
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suggest that a normal monocyte function is important to maintain retinal homeostasis. 
Genetic study did not reveal any link between AMD risk and CCL2 or CCR2 gene 
polymorphism (Despriet et al. 2008). However, monocyte function can be affected by many 
factors, it is entirely possible that similar monocyte functional alterations may exist in AMD 
patients (although they may not be caused by CCL2 or CCR2 deficiency), and these 
functional changes may be responsible for inflammation mediated retinal pathology (with 
or without complement dys-regulation). Further studies on how monocyte function might 
be changed in AMD patients will be essential to develop monocyte-specific immune 
therapy.    
4. Conclusions 
AMD is a multifactorial disease. Old age, environmental risk factors, genetic predispositions 
all work together leading to macular damage. The immune system plays an important role 
in the initiation and progression of the disease. A healthy immune system can prevent overt 
pathology during aging by initiating a para-inflammatory response. Whereas an altered 
immune system either in the complement pathways or the monocyte functions, may fail to 
induce a protective para-inflammatory response. Instead, it may respond aggressively (overt 
inflammation) causing further damage to the aging retina. Complement over activation and 
monocyte malfunction may work together enhancing age-related macular damage. They 
may also work independently contributing to AMD pathology. Due to the complexity of the 
immunomechanism of the disease, there will be no universal immune therapy for AMD. 
Blocking complement activation may benefit patients who have uncontrolled complement 
activity (presumably as a result of complement gene polymorphism), it may make the 
disease worse in patients who do not have a dys-regulated complement system. We suggest 
that complement gene polymorphisms should be used as a guide for complement inhibitors 
therapy in AMD. Modulating monocyte function may be beneficial for patients who have 
monocyte malfunction (may be related CX3CR1 gene polymorphism) (Tuo et al. 2004, Yang 
et al. 2010). Further studies are required to understand the pathways related to monocyte-
mediated macular damage to identify specific target for therapy.   
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